Assessing a Dose‐Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease (PKD) Patients

The purpose of this study is to find a protein (ex. Polycystin 1 or mucin and cadherin like
protein) in the urine that is changed after treatment of hydralazine.

Eligibility Criteria

Inclusion Criteria:

- Confirmed diagnosis of ADPKD

- estimated glomerular filtration rate (eGFR) > 60 ml/min/1.73m^2

Exclusion Criteria:

- History of systemic lupus erythematous or other rheumatologic disorder

- Baseline anti-nuclear antibody (ANA) >1:80 for females and >1:40 for males

- Blood pressure < 120/80 without anti-hypertensive

- Angina pectoris or myocardial infarction in the last 6 months

- Liver disease

- Allergy to hydralazine

Principal Investigator

Kerri McGreal, MD

Study Contact

Debbie Griffin, RN, dgriffin3@kumc.edu, 913-588-7691

Estimated Completion Date

Friday, February 15, 2019

ClinicalTrials.gov #

NCT03423810
04/26/2018